SCHEMBL2904027

SCHEMBL2904027

COc1cc(Cl)ccc1-c1cn(CCCNc2ccc([N+](=O)[O-])c(N)n2)cc1C(=O)NCCN

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.42
GSK3A P49840 3/20 0.42
CDK1 P06493 2/20 0.39
CCNB2 O95067 1/20 0.38
CCNB1 P14635 1/20 0.38
CCNB3 Q8WWL7 1/20 0.38
LMNA P02545 1/20 0.36
SCN10A Q9Y5Y9 1/20 0.36
NPC1 O15118 2/20 0.35
CYP3A4 P08684 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PDCD1LG2 Q9BQ51 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
CYP2C19 P33261 1/20 0.34
G6PD P11413 1/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2908168 0.94 GSK3B (0.42) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2907935 0.91 GSK3B (0.40) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2911606 0.90 GSK3B (0.48) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2911032 0.90 GSK3B (0.45) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2905318 0.88 ATM (0.40) GSK3BGSK3ACDK1LMNAALDH1A1
SCHEMBL2903805 0.88 GSK3B (0.41) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2909914 0.88 GSK3B (0.43) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2912130 0.87 GSK3B (0.48) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2913441 0.86 GSK3B (0.37) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2909817 0.85 GSK3B (0.36) GSK3BGSK3ACDK1CCNB2CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537099-B1 PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 NOVARTIS VACCINES & DIAGNOSTIC (US) 2010-08-11 EP disclosed